Insmed Incorporated Files Shelf Registration Statement
03 Février 2006 - 11:25PM
Business Wire
Insmed Incorporated (Nasdaq: INSM) has filed a shelf registration
statement with the Securities and Exchange Commission (SEC) that
when declared effective by the SEC would allow Insmed to sell up to
$75,000,000 of its common stock, preferred stock or warrants for
common or preferred stock. Insmed may sell these securities in one
or more separate offerings in amounts, at prices and on terms to be
determined at the time of such offer or offerings. This shelf
registration statement is intended to give Insmed flexibility to
take advantage of financing opportunities when and if deemed
appropriate by the Company. Insmed expects to use the proceeds from
any of these offerings for general corporate purposes, including
expanding commercial and marketing efforts; increasing working
capital; funding capital and clinical development expenditures;
acquiring new products or technologies; and making other
investments. A registration statement relating to these securities
has been filed with the Securities and Exchange Commission but has
not yet become effective. These securities may not be sold nor may
offers to buy be accepted prior to the time the registration
statement becomes effective. This press release shall not
constitute an offer to sell, or the solicitation of, an offer to
buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. About Insmed
Incorporated Insmed is a biopharmaceutical company focused on the
development and commercialization of drug candidates for the
treatment of metabolic diseases and endocrine disorders with unmet
medical needs. For more information, please visit www.insmed.com.
Statements included within this press release, which are not
historical in nature, constitute forward-looking statements for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995, including any statement regarding
Insmed's ability to offer its securities or the expected use of the
proceeds from such offer or offering. These statements represent,
among other things, the expectations, beliefs, plans and objectives
of management and/or assumptions underlying or judgments concerning
matters discussed in this document. The inclusion of
forward-looking statements should not be regarded as a
representation by Insmed regarding its ability to offer its
securities pursuant to the shelf registration statement or
regarding the timing of any such offer or offerings. We do not plan
to update these forward-looking statements. You should be aware
that our actual results could differ materially from those
contained in the forward-looking statements due to a number of
risks affecting our business that include, but are not limited to,
our planned clinical trial design, our regulatory and business
strategies, plans and objectives of management and growth
opportunities for existing or proposed products. Such
forward-looking statements are subject to numerous risks and
uncertainties, including risks that product candidates may fail in
the clinic or may not be successfully marketed or manufactured, the
company may lack financial resources to complete development of
product candidates, the FDA may interpret the results of our
studies differently than we have, competing products may be more
successful, demand for new pharmaceutical products may decrease,
the biopharmaceutical industry may experience negative market
trends and other risks detailed from time to time in the company's
filings with the Securities and Exchange Commission. As a result of
these and other risks and uncertainties, actual results may differ
materially from those described in this press release. For further
information with respect to factors that could cause actual results
to differ from expectations, reference is made to reports filed by
the Company with the Securities and Exchange Commission under the
Securities Exchange Act of 1934, as amended. The forward-looking
statements made in this release are made only as of the date hereof
and Insmed disclaims any intention or responsibility for updating
predictions or financial guidance contained in this release.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024